IPF treatment, NXP002, Continues to Show Promise in Preclinical Studies
The inhaled NXP002 achieves significant levels in the lungs and lowers the production of scarring-promoting molecules, a study shows.| Pulmonary Fibrosis News
The inhaled NXP002 achieves significant levels in the lungs and lowers the production of scarring-promoting molecules, a study shows.| Pulmonary Fibrosis News
Inconsistent results of NXP002, a new formulation of tranilast, delayed completion of the package needed for potential clinical trials.| Pulmonary Fibrosis News
Category archive page for News.| Pulmonary Fibrosis News
Learn more about Ofev (nintedanib) for the treatment of idiopathic pulmonary fibrosis (IPF).| Pulmonary Fibrosis News
Read about idiopathic pulmonary fibrosis (IPF) — its risk factors, symptoms, and current ways of treating this interstitial lung disease.| Pulmonary Fibrosis News
Esbriet (pirfenidone) is an oral treatment that has been approved by the U.S. Food and Drug Administration for idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
